Traumatic Optic Neuropathy Treatment Trial 2

• Status: Recruiting
• Trial end date: 2022-12-01
• Target enrollment: 0
• Participant gender: All

Summary

After introducing intravenous erythropoietin (EPO) as an option for treatment of patients with indirect traumatic optic neuropathy in 2011 and publishing non inferiority trial in Oct.2017), TONTT2 is aiming to find out the best dose and timing of EPO administration in this group of patients.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Iran University of Medical Sciences
• Collaborators: Mashhad University of Medical Sciences; Shiraz University of Medical Sciences; Tabriz University of Medical Sciences; Tehran University of Medical Sciences
• Treatments: Epoetin Alfa

Criteria

Inclusion Criteria:

1. Having indirect traumatic optic neuropathy(with normal eye and fundus exam)

2. Trauma to treatment interval of 3 weeks and less

3. Age of 7 years and more

Exclusion Criteria:

1. Direct optic neuropathy,

2. Glaucoma,

3. Any retinopathy

4. Globe laceration

5. Age under 7

6. Hypertension,

7. Polycythemia,

8. Creatinin more than 3 mg/dl,

9. Sensitivity to EPO

10. Patients who have received any other form of treatment for their traumatic optic neuropathy